$ONCS The granting of this patent is gonna raise OncoSec's value, in the eyes of the "big boys," exponentially, especially if they have more than a passing interest in OncoSec's methodology.
In the meantime, long-term holders will need to weather the roller coaster rides that start-ups, such as OncoSec, experience. The pps will eventually catch up to the value of the company.
JMO.
News 
Market Data 
Discover 
